儿童急性淋巴细胞白血病免疫治疗进展  

A progress on immunotherapy for childhood acute lymphoblastic leukemia

作　　者：彭思静 卢婕伦 王子成 曾晓珍 邹亚伟[1] PENG Sijing;LU Jielun;WANG Zicheng;ZENG Xiaozhen;ZOU Yawei(Department of Pediatrics,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;不详)

机构地区：[1]广州医科大学附属第一医院儿科,广州510120 [2]南方医科大学南方医院,广州510515 [3]南方医科大学顺德医院,广东佛山528308

出　　处：《实用医学杂志》2022年第23期2903-2907,共5页The Journal of Practical Medicine

基　　金：广东省自然科学基金项目(编号:2016A030313654)。

摘　　要：急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是儿童最常见的血液恶性肿瘤,近年来儿童ALL患者的预后有了显著改善。然而对于复发/难治ALL患者,常规的化学治疗缓解率低,预后不佳。随着免疫疗法的兴起,针对ALL抗原相关的单克隆抗体和嵌合抗原受体T细胞等免疫治疗已被证实对ALL有效,显著改善复发/难治ALL患者的预后。Acute lymphoblastic leukemia(ALL)is the most common hematologic malignancy in children.The prognosis of ALL in pediatric patients has significantly improved in recent years.However,for pediatric population with relapsed/refractory ALL,conventional chemotherapy has a low remission rate and provides no promising prognosis.With the emergence of immunotherapy,immunotherapies targeting ALL antigen-associated monoclonal antibodies and chimeric antigen receptor T cells have shown to be effective against ALL,significantly improving the prognosis in patients with relapsed/refractory ALL.In this article,we review the immunotherapy for ALL in children.

关 键 词：急性淋巴细胞白血病 免疫疗法 儿童 抗体 嵌合抗原受体 

分 类 号：R733.71[医药卫生—肿瘤]